Jade Therapeutics to use BioTime technology for sustained-release ophthalmic drugs
This article was originally published in Scrip
Alameda, California-based stem cell technology developer BioTime entered into an exclusive sublicense and supply agreement for its HyStem hydrogels and certain other patented technologies with Jade Therapeutics of Salt Lake City, Utah, which is developing a sustained-release drug delivery platform for ophthalmic indications.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.